Lai, K.K.H.; Aljufairi, F.M.A.A.; Li, C.L.; Ngai, A.K.Y.; Yeung, C.S.K.; Fong, R.H.Y.; Yip, W.W.K.; Young, A.L.; Pang, C.P.; Chong, K.K.L.
Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy. J. Clin. Med. 2023, 12, 3244.
https://doi.org/10.3390/jcm12093244
AMA Style
Lai KKH, Aljufairi FMAA, Li CL, Ngai AKY, Yeung CSK, Fong RHY, Yip WWK, Young AL, Pang CP, Chong KKL.
Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy. Journal of Clinical Medicine. 2023; 12(9):3244.
https://doi.org/10.3390/jcm12093244
Chicago/Turabian Style
Lai, Kenneth K. H., Fatema Mohamed Ali Abdulla Aljufairi, Chi Lai Li, Amanda K. Y. Ngai, Carly S. K. Yeung, Ryan H. Y. Fong, Wilson W. K. Yip, Alvin L. Young, Chi Pui Pang, and Kelvin K. L. Chong.
2023. "Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy" Journal of Clinical Medicine 12, no. 9: 3244.
https://doi.org/10.3390/jcm12093244
APA Style
Lai, K. K. H., Aljufairi, F. M. A. A., Li, C. L., Ngai, A. K. Y., Yeung, C. S. K., Fong, R. H. Y., Yip, W. W. K., Young, A. L., Pang, C. P., & Chong, K. K. L.
(2023). Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy. Journal of Clinical Medicine, 12(9), 3244.
https://doi.org/10.3390/jcm12093244
